Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Investment analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Halozyme Therapeutics in a report issued on Tuesday, January 7th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.98 per share for the quarter, up from their previous estimate of $0.97. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler boosted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research report on Monday, November 4th. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, Wells Fargo & Company lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Price Performance

HALO traded up $2.57 during midday trading on Thursday, hitting $53.76. The company had a trading volume of 2,668,262 shares, compared to its average volume of 1,711,198. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a market capitalization of $6.84 billion, a PE ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm's 50-day simple moving average is $50.16 and its 200-day simple moving average is $54.00.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company's stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HALO. Commonwealth Equity Services LLC lifted its stake in Halozyme Therapeutics by 34.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 20,382 shares of the biopharmaceutical company's stock valued at $1,067,000 after acquiring an additional 5,210 shares in the last quarter. Private Advisor Group LLC grew its position in Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock valued at $1,191,000 after purchasing an additional 412 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at $195,000. Texas Permanent School Fund Corp lifted its position in Halozyme Therapeutics by 6.0% during the 2nd quarter. Texas Permanent School Fund Corp now owns 121,635 shares of the biopharmaceutical company's stock worth $6,369,000 after buying an additional 6,890 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Halozyme Therapeutics by 9.7% during the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock worth $43,002,000 after buying an additional 72,544 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.